Clinical Trials
13 trialsNCT05268003 2026-04-27
A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01570868 2025-12-08
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03576547 2025-05-08
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02398825 2025-01-17
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT04554459 2024-08-14
Pona-CELL
Institute of Hematology and Blood Transfusion, Czech Republic
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03807479 2023-09-14
PONS
GWT-TUD GmbH
Phase 2 Terminated
NCT02448095 2022-10-26
Retrospective Evaluation of CML Patients in the National Compassionate Program
Gruppo Italiano Malattie EMatologiche dell'Adulto
Terminated
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01838642 2017-02-15
Ponatinib for Advanced Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01761747 2014-12-23
Ponatinib for Squamous Cell Lung and Head and Neck Cancers
Dana-Farber Cancer Institute
Phase 2/3 Terminated
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated